The goal of this clinical trial is to find the best dose and learn more about the safety and effectiveness of maplirpacept (PF-07901801) in patients with advanced hematologic malignancies, including Lymphoma, Leukemia, and Multiple Myeloma.
SparkCures ID | 1006 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 189 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Key Inclusion Criteria (Phase 1a and Phase 1b, all Cohorts):
Key Exclusion Criteria (Phase 1a and Phase 1b, all Cohorts):
Please visit the ClinicalTrials.gov page for historical site information.
View CentersLearn more about how we work with trial sponsors